Long Term Study of Avonex Therapy Following a First Attack of Multiple Sclerosis

NCT00179478 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

155

Enrollment

OTHER

Sponsor class

Conditions

Multiple Sclerosis
Optic Neuritis
Transverse Myelitis
Acute Brainstem/Cerebellar Syndrome

Interventions

DRUG: interferon beta 1a 30 ug IM once weekly

Sponsor

Beth Israel Deaconess Medical Center

Collaborators

[object Object]